• Accueil >
  • Publications >
  • Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)

8 nov. 2016Oncotarget

DOI : 10.18632/oncotarget.12172

Auteurs

Loic Lebellec, François Bertucci, Emmanuelle Tresch-Bruneel, Emmanuelle Bompas, Yves Toiron, Luc Camoin, Olivier Mir, Valerie Laurence, Stephanie Clisant, Emilie Decoupigny, Jean-Yves Blay, Anthony Goncalves, Nicolas Penel